Journal article icon

Journal article

Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/− cetuximab in oesophageal cancer

Abstract:

The SCOPE-1 study tested the role of adding cetuximab to conventional definitive chemoradiotherapy (dCRT), and demonstrated greater toxicity and worse survival outcomes. We present the long-term outcomes and patterns of recurrence.SCOPE-1 was a phase II/III trial in which patients were randomised to cisplatin 60 mg m-2 (day 1) and capecitabine 625 mg m-2 bd (days 1-21) for four cycles +/- cetuximab 400 mg m-2 day 1 then by 250 mg m-2 weekly. Radiotherapy consisted of 50 Gy/25# given concurren...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1038/bjc.2017.21

Authors


More by this author
Role:
Author
ORCID:
0000-0003-1206-8355
More from this funder
Name:
Medical Research Council
Grant:
MR/K025643/1
More from this funder
Name:
Department of Health
Grant:
NF-SI-0514-10114
More from this funder
Name:
Cancer Research UK
Grant:
15954
Publisher:
Springer Nature
Journal:
British Journal of Cancer More from this journal
Volume:
116
Issue:
6
Pages:
709-716
Publication date:
2017-02-14
Acceptance date:
2017-01-16
DOI:
EISSN:
1532-1827
ISSN:
0007-0920
Pmid:
28196063
Language:
English
Keywords:
Pubs id:
pubs:680494
UUID:
uuid:67ac59ee-a68d-4756-bbe9-20c68f81c630
Local pid:
pubs:680494
Source identifiers:
680494
Deposit date:
2019-06-20

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP